Aili He

Aili He

Individual profiles

Graduated from Xi’an Medical University in 1989 and then worked in the second Affiliated Hospital of Xi’an Jiaotong University. Obtained master's and doctor's degrees of clinical medicine in few years. Now worked as the director of department of Internal Medicine, director of Hematology, professor, chief physician and doctoral supervisor of the Second Affiliated Hospital of Xi 'an Jiaotong University. As a member of committee of society of Hematological Malignancy of China Anti-Cancer Association, Integrated Hematology Professional Committee of Chinese Medical Doctor Association and Hematology Branch of China Medical Women's Association. Also served as the deputy director of Shaanxi Anti-Cancer Association, the president of Hematology Branch of Shaanxi Medical Association, the chairman designated of the Hematological Oncology Branch of Shaanxi Anti-Cancer Association and the vice Chairman of Clinical Immunology of Shaanxi Provincial Society.

Major Research Direction:

Research of immunotherapy and the mechanism of immune escape of hematological malignancies.

Research project:

Presided two projects of National Natural Science Foundation of China, one major national special project for new drug innovation Project and two projects of Science and Technology Overall Innovation Plan of Shaanxi Province. Published more than 30 SCI papers as the first author or corresponding author, and a single paper has been cited nearly 200 times. Participated in the publication of 3 monographs and obtained 2 national invention patents. Published 6 teaching papers as the first author and corresponding author and 4 teaching papers as the second author. As an editorial board member of "Journal of Xi'an Jiaotong University (Medical Edition)" and "Western Medicine", and reviewer of "Journal of Zhejiang University Medical Edition". Won the 9th Shaanxi Provincial Youth Science and Technology Award and 3 second prizes of Shaanxi Province Science and Technology Award.

Presided over the development of two new technological therapies in the hospital: "Sequential Treatment of Acute Promyelocytic Leukemia with All-Trans Retinoic Acid, Chemotherapy and Leukemia" and "Unrelated Hematopoietic Stem Cell Transplantation for Hematological Malignancies". Developed chimeric antigen receptor T (CART) cells for the treatment of relapsed and refractory multiple myeloma, ranking the world's leading level, and has given conference reports at domestic and foreign conferences for many times in the past few years.

Recently published papers

1. Wu, Dong, Jiyu Miao, Jinsong Hu, Fangmei Li, Dandan Gao, Hongli Chen, Yuandong Feng, Ying Shen, and Aili He. "PSMB7 is a key gene involved in Multiple Myeloma Development and Drug Resistance to Bortezomib." Frontiers in Oncology 11 (2021): 2916.

2. Liu, Zeshi, Lu Bai, Jiayun Liu, Jing Lei, Xinghui Gao, Fred C. Tenover, Ke Lei, Yi-Wei Tang, Yan Geng, and Aili He. "Parallel Validation of the NG-Test Carba 5 and the Xpert Carba-R for Detection and Characterization of Carbapenem-Resistant Enterobacterales Causing Bloodstream Infections." The Journal of Molecular Diagnostics (2021).

3. Shen, Ying, Yuandong Feng, Fangmei Li, Yachun Jia, Yue Peng, Wanhong Zhao, Jinsong Hu, and Aili He. "lncRNA ST3GAL6AS1 promotes invasion by inhibiting hnRNPA2B1mediated ST3GAL6 expression in multiple myeloma." International Journal of Oncology 58, no. 4 (2021): 1-1.

4. Liu, Rui, Xiaman Wang, Ying Shen, and Aili He. "Long non-coding RNA-based glycolysis-targeted cancer therapy: feasibility, progression and limitations." Molecular Biology Reports (2021): 1-15.

5. Wu, Dong, Peihua Zhang, Fangmei Li, Ying Shen, Hongli Chen, Yuandong Feng, Aili He, and Fangxia Wang. "CD138-multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient." Aging (Albany NY) 12, no. 22 (2020): 23067

6. Bai J, He A, Huang C, et al. Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia (vol 12, 49, 2014) [J]. PROTEOME SCIENCE, 2020, 18(1).

7. Wang, Xiaman, Yuandong Feng, Peihua Zhang, Hongli Chen, Ju Bai, Fangxia Wang, and Aili He. "miR‐582‐5p serves as an antioncogenic biomarker in intermediate risk AML with normal cytogenetics and could inhibit proliferation and induce apoptosis of leukemia cells." Cell Biology International 44, no. 10 (2020): 2021-2030.

8. Peng, Yue, Dong Wu, Fangmei Li, Peihua Zhang, Yuandong Feng, and Aili He. "Identification of key biomarkers associated with cell adhesion in multiple myeloma by integrated bioinformatics analysis." Cancer Cell International 20, no. 1 (2020): 1-16.

9. Peng, Yue, Fangmei Li, Peihua Zhang, Xiaman Wang, Ying Shen, Yuandong Feng, Yachun Jia, Ru Zhang, Jinsong Hu, and Aili He. "IGF-1 promotes multiple myeloma progression through PI3K/Akt-mediated epithelial-mesenchymal transition." Life sciences 249 (2020): 117503.

10. Peng, Yue, Xiaman Wang, Ying Shen, Fangmei Li, Ru Zhang, Yachun Jia, and Aili He. "Insulin-like Growth Factor-1-Induced Epithelial-Mesenchymal Transition Promotes Multiple Myeloma Progression." (2019): 5541-5541.

11. Shen, Y., Jia, Y., Zhang, R., Chen, H., Feng, Y., Wang, F.X., Zhao, W., Wang, J., He, A., Yang, Y. and Xu, Y., 2019. Using circ-ANAPC7 as a novel type of biomarker in the monitoring of acute myeloid leukemia.

12. Shen, Ying, Fangmei Li, Dong Wu, Yue Peng, Wanhong Zhao, Yun Yang, Jianli Wang, Ju Bai, Yan Xu, and Aili He. "Identification of ST3GAL6-AS1 Interactive Protein in Multiple Myeloma." (2019): 4365-4365.

Contact information

E-mail: heaili@mail.xjtu.edu.cn